SCHEMBL24904299

SCHEMBL24904299

O=C1NC(S)N/C1=C\c1ccc2ncsc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 20/20 0.62
▸ DYRK1A Q13627 20/20 0.62
▸ DYRK1B Q9Y463 20/20 0.62
▸ DYRK2 Q92630 19/20 0.62
▸ CSNK2A2 P19784 2/20 0.62
▸ CSNK2B P67870 2/20 0.62
▸ CSNK2A1 P68400 2/20 0.62
▸ CLK4 Q9HAZ1 19/20 0.57
▸ CLK2 P49760 18/20 0.57
▸ DYRK3 O43781 17/20 0.57
▸ CLK3 P49761 17/20 0.57
▸ DYRK4 Q9NR20 17/20 0.57
▸ GSK3B P49841 14/20 0.57
▸ PIK3CD O00329 1/20 0.54
▸ PRKCB P05771 1/20 0.54
▸ PIK3CA P42336 1/20 0.54
▸ PIK3CG P48736 1/20 0.54
▸ HASPIN Q8TF76 1/20 0.54
▸ CDK5 Q00535 5/20 0.54
▸ CDK5R1 Q15078 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23510452 0.80 CLK1 (0.54) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL28945469 0.79 CLK1 (0.54) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL23510720 0.78 CLK1 (0.52) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL24904284 0.78 CLK1 (0.55) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL23499923 0.76 CLK1 (1.00) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL30145013 0.76 CLK1 (1.00) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL2881987 0.73 DYRK1A (0.79) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL2881990 0.73 DYRK1A (0.79) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL23510637 0.73 CLK1 (0.64) CLK1DYRK1ADYRK1BDYRK2CSNK2A2
SCHEMBL30275520 0.72 DYRK1A (0.60) CLK1DYRK1ADYRK1BDYRK2CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TONGJI UNIVERSITY (CN) 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025301-A1 Novel Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases TNNI3, TNNT2, MKI67 CLK1 2884/4885DYRK1A 3319/4885DYRK1B 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback